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This study aims to investigate the effect of endothelial-monocyte activating polypeptide
II (EMAP II) on human glioblastoma (GBM) cells and glioblastoma stem cells (GSCs)
as well as its possible mechanisms. In this study, EMAP II inhibited the cell viability
and decreased the mitochondrial membrane potential in human GBM cells and GSCs,
and autophagy inhibitor 3-methyl adenine (3-MA) blocked these effects. Autophagic
vacuoles were formed in these cells after EMAP II treatment and this phenomenon
was blocked by 3-MA. In addition, the up-regulation of microtubule-associated protein-
1 light chain-3 (LC3)-II and the down-regulation of autophagic degraded substrate
p62/SQSTM1 caused by EMAP II were observed. Cells treated with EMAP-II inhibited
the PI3K/Akt/mTOR signal pathway, and PI3K/Akt agonist insulin-like growth factor-1
(IGF-1) blocked the effect of EMAP II on the expression of LC3-II and p62/SQSTM1.
Cells exposed to EMAP-II experienced mitophagy and ER stress. Furthermore, the
inhibition of cell proliferation, migration and invasion of GBM cells and GSCs were more
remarkable by the combination of EMAP II and rapamycin than either agent alone in vitro
and in vivo. The current study demonstrated that the cytotoxicity of EMAP II in human
GBM cells and GSCs was induced by autophagy, accompanied by the inhibition of
PI3K/Akt/mTOR signal pathway, mitophagy and ER stress. The combination of EMAP II
with rapamycin demonstrated the inhibitory effect on the malignant biological behaviors
of human GBM cells and GSCs in vitro and in vivo.
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INTRODUCTION
Glioblastoma (GBM) is the most common and aggressive human
brain tumor characterized by local invasion, microvascular
proliferation, and therapeutic resistance (Omuro and DeAngelis,
2013). Despite therapeutic advances in the last several decades,
the outcome of GBM patients still poor with a median survival
of only 12–15 months (Tanaka et al., 2013). Glioblastoma
stem cells (GSCs) correspond to a tumor cell subpopulation,
display extensive self-renewal, multilineage diﬀerentiation, and
propagation of tumors (Singh et al., 2004; Bao et al., 2006;
Hadjipanayis and Van Meir, 2009; Piccirillo et al., 2009).
Considerable evidence have proved that GSCs are responsible
for tumor angiogenesis, immune evasion, therapeutic resistance,
and tumor recurrence (Bao et al., 2006; Visvader and Lindeman,
2008). Therefore, treatments that improve targeting of GSCs are
urgent needed to be provided.
Accumulating evidence showed that diﬀerent manners of
programmed cell death could trigger diﬀerent biological events.
Autophagy, also known as type II programmed cell death,
can induce programmed cell death which further propels
chemotherapy and/or radiotherapy-mediated cytotoxicity in
apoptosis-resistant tumor cells (White, 2012). The role of
autophagy in various physiological and pathological processes is
currently being investigated. Drug-induced autophagy has been
corroborated to have anti-inﬂammatory and anti-tumor eﬀects,
and it has been conﬁrmed that the autophagic response could
strengthen the anti-tumor eﬀects of drugs (Chen and Karantza-
Wadsworth, 2009; Al-Ejeh et al., 2010). Therapeutic studies have
shown that glioma cells could undergo autophagy by drugs,
which triggers autophagic cell death. Clinical trials proved that
temozolomide (TMZ), which achieved better curative eﬀects in
the patients with apoptosis-resistant GBM (Kanzawa et al., 2004),
could induce autophagy in GBM cells as well (Minniti et al.,
2008). Valproic acid (VPA) was also conﬁrmed to be able to
cause cell death of glioma cell lines by inducing autophagy (Fu
et al., 2010). Recent study also showed that cannabidiol inhibits
GSCs proliferation by inducing autophagy in a transient receptor
potential vanilloid-2(TRPV2)-dependent manner (Nabissi et al.,
2015). Taken together, inducing autophagic death might be one
of the main mechanisms of anti-neoplastic drugs in human GBM
cells and GSCs.
Endothelial-monocyte-activating polypeptide II (EMAP II)
is a protein extrated from methylcholantherene A (Meth A)
transformed ﬁbrosarcoma (Kao et al., 1994). Low-dose EMAP II
has been conﬁrmed to increase the blood-tumor barrier (BTB)
permeability by opening tight junction (TJ) via Rho A, PKC or
other signal pathways (Li et al., 2012, 2015; Xie et al., 2012).
Furthermore, EMAP II has been conﬁrmed as a component of
the immunosuppressive pathway in several solid tumors (Murray
et al., 2004a,b; Faisal et al., 2007). EMAP II could suppress the
growth of primary and metastatic tumors and induce apoptosis
in growing endothelial cells (Schwarz et al., 2010a). Elevated
EMAP II expression was associated with lymphocyte apoptosis
and lack of metastases in colon cancer patients (Stathaki et al.,
2014). The in vivo study reported that EMAP II attenuated the
primary tumor growth of rat C6 glioma cells (Schwarz and
Schwarz, 2004). In pancreatic cancer, EMAP II alone or in
combination with bortezomib have anti-proliferative and pro-
apoptotic eﬀects, and signiﬁcantly reduced B-cell lymphoma-2
(Bcl-2) expression (Awasthi et al., 2010). Beclin-1 was found to
induce autophagy, and Bcl-2 could inhibit its function by binding
its BH3 domain (Guertin and Sabatini, 2005), suggesting that
EMAP II might induce autophagy. Therefore, whether EMAP-II
induces the autophagy of human GBM cells and GSCs needs to
be explored urgently.
In the present study, we investigated whether EMAP II induce
cell autophagy in human GBM cells and GSCs, and its potential
mechanisms. Further, we examined the eﬀect of the combination
of EMAP II with rapamycin on biological behaviors of human
GBM cells and GSCs in vitro and in vivo.
MATERIALS AND METHODS
Reagents
Dulbecco’s modiﬁed eagle’s medium (DMEM), fetal bovine
serum (FBS), DMEM/F-12 medium and basic ﬁbroblast
growth factor (bFGF), epidermal growth factor (EGF),
2% B27 and MitoTracker Deep Red FM were purchased
from Life Technologies Corporation (Carlsbad, CA, USA).
EMAP II, rapamycin, dimethyl sulfoxide (DMSO), 3-methyl
adenine (3-MA), Z-VAD-fmk (Z-VAD), tauroursodeoxycholate
(TUDC), and laminin were purchased from Sigma–Aldrich
(St. Louis, MO, USA). Cell counting kit-8 (CCK8), DAPI,
Alexa Fluor 488, Alexa Fluor 555, and BCA protein
assay kit were purchased from Beyotime Institute of
Biotechnology (Jiangsu, China). 5,5,6,6′-tetrachloro-1,1′ ,3,3′-
tetraethyl-benzimidazol-carbo-cyanine iodide (JC-1) apoptosis
detection kits were purchased from Becton Dickinson
Bioscience (San Jose, CA, USA). IGF-1 was purchased from
PeproTech (St.Louis, MO, USA). Primary antibodies against
microtubule-associated protein 1 light chain 3 (LC3, ab63817)
and p62/SQSMT1 (ab56416) were purchased from Abcam
(Cambridge, MA, USA). Primary antibodies against p-PI3K
(#4228), PI3K (#4257), p-Akt (Ser473) (#9271), Akt (#9272),
p-mTOR (Ser 2448) (#2971), mTOR (#2972), GRP78 (#3183),
p-eIF2α (#3398), eIF2α (#5324), and CHOP (#5554) antibodies
were from Cell Signaling Technology (Beverly, MA, USA). Anti-
GAPDH (sc-365062) and the secondary antibodies conjugated
with horseradish peroxidase were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Primary antibodies
against TOMM20 (612278), TIMM23 (611222), and Matrigel
were purchased from BD Biosciences (Franklin Lakes, NJ, USA).
Cell Culture and Treatment Conditions
Human GBM cell lines (U87 and U118) were obtained from
Shanghai Institutes for Biological Sciences Cell Resource Center
and were cultured in DMEM with 10% FBS in a humidiﬁed
atmosphere of 5% CO2 at 37◦C. GSCs were isolated from
fresh surgical specimens of human GBM tissues following the
procedures as described previously (Singh et al., 2003; Yao
et al., 2015). GSCs were maintained in DMEM/F-12 medium
supplemented with bFGF (20 ng/ml), EGF (20 ng/ml) and 2%
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B27. The ﬁve independent GSCs were isolated from 5 GBM
patients. All the patients provided written informed consent, and
the study was approved by the Ethics Committee of Shengjing
Hospital of China Medical University. Only early passage cell line
were used for the study. Information of patient tissues was listed
in Supplementary Table S1.
For the experiments, cells were treated with EMAP II at
diﬀerent concentrations (0.005 nM, 0.05 nM, 0.5 nM, and 5 nM,
diluted with saline solution) for 0.5, 1, 2, 3, and 6 h, and then
the medium was replaced with fresh medium for 24 h. However,
cells in control group were maintained in medium containing the
same concentration of saline. According to the related results,
0.05 nM and 0.5 h was considered as the optimum dosage
and time, respectively. Furthermore, cells were pretreated with
2 mM 3-MA, 100 μM Z-VAD, 2 mM 3-MA+100 μM Z-VAD,
10 nM IGF-1, 500 μM TUDC, and 50 nM rapamycin in diﬀerent
experiments in this study.
Cell Viability Assay
Cell viability was measured using CCK8 according to the
manufacturer’s instructions. The principle of the cell viability
assay is that mitochondrial activity is constant for most viable
cells and thereby an increase or decrease in the number of viable
cells is linearly related to mitochondrial activity. CCK8 is based
on the WST-8, which is reduced by dehydrogenases in the cells
giving an orange colored formazan. The mitochondrial activity
of the cells is reﬂected by the formazan. Thus, any increase or
decrease in viable cell number can be detected by measuring
formazan concentration. Brieﬂy, cells were seeded in 96-well
plate with 200 μl medium, incubated for 24 h under standard
conditions and treated with reagents for indicated time. At the
end of the time point, 20 μl of CCK8 was added to each well
and incubated for additional 2 h, and the absorbance was ﬁnally
measured at the wavelength of 450 nm.
JC-1 Assay for Flow Cytometry
Cells were seeded in 6-well plate with 2 ml medium, incubated
for 24 h and then treated with reagents for indicated time. After
incubated with 10 μg/ml JC-1 at 37◦C for 30 min, cells were
washed once with PBS and resuspended with 500 μl PBS. The
samples were immediately measured by ﬂow cytometer. In living
cells, JC-1 accumulates in mitochondria forming red ﬂuorescent
aggregates, JC-1 exists mainly in green ﬂuorescent monomeric
form once mitochondria membrane potential is depolarized. The
results were analyzed by cell quest software. JC-1 green and red
ﬂuorescence was recorded on FL1 and FL2 channels, respectively.
The dots distributed in the upper right quadrant (UR) and lower
right quadrant (LR).
Transmission Electron Microscopy (TEM)
Analysis
Cells were ﬁxed with 2.5% glutaraldehyde at 4◦C for 2 h and
subsequently ﬁxed with 1% OsO4-0.15 MNa cacodylate/HCl (pH
7.4) for 30 min. Then cells were dehydrated in graded ethanol
and polymerized at 60◦C for 48 h. Samples were prepared and
analyzed with a JEM 1230 transmission electron microscope
(JEM-1200EX; n = 5, each) at 60 kV. Micrographs were taken
at ×5,000 or at ×10,000.
Immunofluorescence Assay
The U87 and U118 cells were seeded on chamber slides (or GSCs
were seeded on chamber slides pre-coated with fresh laminin for
adherent culture) for 24 h, then treated with 0.05 nM EMAP
II for 0.5 h or 0.05 nM EMAP II for indicated time. Cells
were stained with LysoTracker Red at a ﬁnal concentration of
50 nM, or MitoTracker Deep Red FM at a ﬁnal concentration
of 100 nM. Cells were ﬁxed in 4% paraformaldehyde for 20 min,
and then incubated with 5% BSA for 2 h at room temperature.
Primary antibody staining was performed for LC3 (or LC3
and p62/SQSMT1). After that, cells were washed and incubated
with a secondary antibody conjugated to Alexa Fluor 488 and
Alexa Fluor 555. Nuclei were stained with 0.5 μg/ml DAPI.
The cells were visualized using immunoﬂuorescence microscopy
(Olympus, Tokyo, Japan).
Western Blot Assay
Cells treated with reagents for indicated time were lysed
in RIPA buﬀer supplemented with a proteinase inhibitor
(10 mg/ml aprotinin, 10 mg/ml phenyl-methylsulfonyl chloride
(PMSF) and 50 mM sodium orthovanadate). Cell extracts were
quantiﬁed using the BCA protein assay kit and equal amounts
of proteins were separated by SDS-PAGE. Gels were then
transferred to PVDF membranes, blocked with 5% non-fat
dry milk and incubated with the primary antibody solution.
Alternatively, primary phospho-antibodies were diluted in 5%
BSA in TBST overnight at 4◦C. The membrane was washed
with TBST and incubated with an HRP-conjugated secondary
antibody solution. After subsequent washes, immunoblots were
visualized by enhanced chemiluminescence (ECL kit, Santa Cruz
Biotechnology). Autoradio-graphic images were scanned and
integrated density value (IDV) of protein bands were quantiﬁed
by ChemImager 5500 software.
Scratch Wound Healing Assay
Scratch wound healing assay was adapted to evaluate the
migration ability of U87 and U118 cells. Brieﬂy, cells were seeded
on 6-well plates at the density of 1 × 104 per well until they
reached 80% conﬂuence. Scratching wounds were created in the
monolayer of conﬂuent cells with a pipette tip. The width of
wounds was assessed to be the same at the beginning of the
experiments. The wells were rinsed with PBS three times to
remove ﬂoating cells and debris. Cells were treated with EMAP
II, rapamycin or the combination of EMAP II and rapamycin
at indicated time. Wound healing was measured and recorded
photographically.
Transwell Assays
The migration and invasion abilities of U87, U118, and GSCs
were detected using 24-well transwell chambers with 8 μm
pore size (Corning Costar). Cells were resuspended in medium
and seeded on the upper chambers (without Matrigel for cell
migration assay) or seeded on the upper chambers pre-coated
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with Matrigel (for cell invasion assay). After incubated for 24 h,
the inserts were taken out and cells remained on the upper surface
of the ﬁlters were removed carefully with a cotton wool swab.
The migrated and invaded cells were washed with PBS and ﬁxed
with methanol and glacial acetic acid (mixed at 3:1) for 30 min
at room temperature and stained using Giemsa stain for 15 min.
The average number of cells was counted in six random ﬁelds.
In Vivo Xenograft Study
Four-week-old BALB/C athymic nude mice were supplied by
Cancer Institute of the Chinese Academy of Medical Science.
All experiments were carried out under the approval of the
Administrative Panel on Laboratory Animal Care of Shengjing
Hospital. All animals had access to food and water ad libitum. For
subcutaneous implantation, a total of 3 × 105 cells suspended in
100 μl medium was injected into the right ﬂank regions of nude
mice. Tumor volume was calculated according to the formula:
volume (mm3) = (a × b2)/2 (where a is the largest superﬁcial
diameter and b is the smallest superﬁcial diameter). When the
tumors grew to about 80 mm3, the tumor-bearing mice were
randomly assigned to the control group (treated with 0.05 nM
saline), EMAP-II treatment group (treated with 80 ng/kg EMAP-
II), rapamycin treatment group (treated with 50 nM rapamycin),
and the combination of EMAP-II and rapamycin group (treated
with 50 nM rapamycin and 80 ng/kg EMAP-II). The tumor-
bearing mice were treated as described above every 12 h for
18 weeks. Tumor volume was measured every other day for
18 weeks.
Statistical Analysis
All results were expressed as mean ± SD for each group and
analyzed by use of SPSS 18.0 software. One-way ANOVAand post
hoc comparisons (Bonferroni test) were utilized to determine
the signiﬁcant diﬀerences among multiple groups. P < 0.05 was
considered statistically signiﬁcant.
RESULTS
Cytotoxicity of EMAP II in Human GBM
Cells and GSCs
The eﬀects of EMAP II on the cell viability of human GBM cells
and GSCs were evaluated at indicated time and concentration
(the time line of experiments was shown in Figure 1A). As
shown in Figure 1B, the cell viability of U87, U118, and
GSCs were inhibited by EMAP II in time- and dose-dependent
patterns. Compared with the control group, the cell viability was
signiﬁcantly decreased at 0.5 h with the treatments of 0.05, 0.5,
and 5 nM EMAP II (P < 0.01). The cell viability of U87, U118,
and GSCs were inhibited at 0.5, 1, and 2 h in groups of 0.05, 0.5,
and 5 nM, respectively (P < 0.01), whereas there was no obvious
diﬀerence among three groups (P > 0.05). Thus, 0.05 nM at 0.5 h
were selected as the optimum concentration and time point in the
subsequent experiments, respectively. We further investigated
whether the inhibitory eﬀect of EMAP II on cell viability was
associated with the induced autophagy and apoptosis. Cells were
pretreated with autophagy inhibitor 3-MA or caspase inhibitor
Z-VAD alone or in combination. As shown in Figure 1C, the
cell viability was inhibited in EMAP II and EMAP II+Z-VAD
groups compared with control group (P < 0.01), and there was
no signiﬁcant diﬀerence between these groups (P > 0.05). In
addition, the cell viability was increased in EMAPII+3-MAgroup
compared with EMAP II group (P < 0.01), suggesting that 3-MA
blocked the inhibitory eﬀect of EMAP II on the cell viability.
JC-1 staining was used to further detect the eﬀect of EMAP II
on mitochondrial membrane potential (MMP) in human GBM
cells and GSCs. As shown in Figure 1D, results showed that the
ratio of JC-1monomer increased signiﬁcantly and reached a peak
at 0.5 h (P < 0.01). Then it decreased, and ﬁnally returned to
the level of control group. Since the increase of JC-1 monomer
ratio is an indicator of MMP, the above result demonstrated that
EMAP II decreased the MMP of U87, U118, and GSCs in a time-
dependent manner (P < 0.01). In addition, the ratio of JC-1
monomer in EMAP II +3-MA group was decreased compared
with that in EMAP II group, suggesting that 3-MA blocked the
EMAP II-induced decrease in MMP. The above results suggested
that inhibitory eﬀects of EMAP II on the cell viability and MMP
might be associated with cell autophagy in human GBM cells and
GSCs.
EMAP II Induced Cell Autophagy in
Human GBM Cells and GSCs
Due to the fact that the cell viability and MMP were not changed
in cells treated with 3-MA alone, the following experiments were
performed without cells treated with 3-MA alone. TEM was used
to observe the eﬀects of EMAP II on the ultrastructural changes
in human GBM cells and GSCs. As shown in Figure 2A, the
autophagic vacuoles were positive in U87 cells in the 0.05 nM
EMAP II for 0.5 h group and negative in the control group and
the EMAP II+3-MA group. The same results were also observed
in U118 cells and GSCs. As shown in Figure 2B, cells were stained
with anti-LC3 and LysoTracker Red by immunoﬂuorescence.
EMAP II signiﬁcantly increased the punctate distribution and
density of LC3 as well as autophagic vacuoles numbers in
U87, U118, and GSCs (P < 0.01). Co-treatment with 3-MA
reduced the punctate distribution and density of LC3 as well as
autophagic vacuoles numbers (P < 0.01). In addition, we found
that there was a signiﬁcant overlap between LC3 and lysosomal
signals in EMAP II treated cells (P < 0.01), suggesting that
autophagosome–lysosome fusion was not inhibited by EMAP II.
These results suggested that EMAP II could induce autophagic
vacuoles formation in human GBM cells and GSCs, and 3-MA
could block this eﬀect.
EMAP II Regulated the Expression of
LC3 and p62/SQSTM1 in Human GBM
Cells and GSCs
Eﬀects of EMAP II on the expression and distribution of LC3-
II and p62/SQSTM1 were detected by Western blot assay and
immunoﬂuorescence assay, respectively. As shown in Figure 3A,
Western blot assay was used to investigate the eﬀects of EMAP
II (0.005, 0.05, 0.5, and 5 nM) on the expression of LC3-I and
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FIGURE 1 | Effect of endothelial-monocyte activating polypeptide II (EMAP II) on human GBM cells and GSCs. (A) Timeline of the research with EMAP II.
(B) Effect of EMAP II on the cell viability of U87, U118, and GSCs after treatment with 0.005 nM, 0.05 nM, 0.5 nM, and 5 nM EMAP II for 0.5, 1, 2, 3, and 6 h.
(C) Effects of EMAP II, 3-MA and Z-VAD on the cell viability of U87, U118 and GSCs after treatment with 0.05 nM EMAP-II for 0.5 h. (D) Effects of EMAP II, 3-MA,
and Z-VAD on MMP of U87, U118, and GSCs by JC-1 staining for flow cytometry. Values represented the means ± SD (n = 5, each). ∗∗P < 0.01 vs. control group,
##P < 0.01 vs. EMAP II group.
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FIGURE 2 | Effect of EMAP II and 3-MA on the ultrastructural change in human GBM cells and GSCs. (A) Effect of EMAP II and 3-MA on the ultrastructural
change in U87, U118, and GSCs. Arrows show autophagic vacuoles. (B) The colocalization of LC3 and LysoTracker Red in U87, U118, and GSCs. Relative mean
optical density of LC3 and LysoTracker Red, and the co-localization of LC3 and LysoTracker Red quantified. Pictures are respective magnification (n = 4, each).
Scale bar = 20 μm. ∗∗P < 0.01 vs. control group, ##P < 0.01 vs. EMAP II group.
LC3-II in U87, U118 and GSCs at 0.5 h. Compared with the
control group, LC3-II/LC3-I expression signiﬁcantly increased
in 0.05, 0.5, and 5 nM EMAP II groups (P < 0.01), whereas
it did not change in 0.005 nM group. There was no signiﬁcant
diﬀerence among these three groups (P > 0.05). Further, cells
were treated with EMAP II (0.05 nM) at indicated time and
pretreated with 3-MA to examine the LC3 and p62/SQSTM1
expression. As shown in Figure 3B, LC3-II/LC3-I expression was
signiﬁcantly increased at 0.5, 1, and 2 h after 0.05 nM EMAP
II treatment compared with the control group (P < 0.01). In
addition, LC3-II/LC3-I expression was decreased in EMAPII+3-
MA group compared with EMAP II group (P < 0.01), suggesting
that 3-MA blocked the eﬀect of EMAP II on the LC3-
II/LC3-I expression. Meanwhile, the p62/SQSTM1 expression
was signiﬁcantly decreased at 0.5, 1, and 2 h after 0.05 nM
EMAP II treatment (P < 0.01). In addition, the p62/SQSTM1
expression was increased in EMAPII+3-MA group compared
with EMAP II group (P < 0.01), suggesting that 3-MA blocked
the inhibitory eﬀect of EMAP II on the p62/SQSTM1 expression.
The immunoﬂuorescence assay of LC3-II and p62/SQSTM1
displayed similar results as above (Figure 3C). These results
suggested that EMAP II induced cell autophagy by regulating the
expression of LC3 and p62/SQSTM1 in human GBM cells and
GSCs.
EMAP II Blocked the PI3K/Akt/mTOR
Pathway in Human GBM Cells and GSCs
As shown in Figure 4A, the expression of p-PI3K/PI3K and
p-PI3K/GAPDH were decreased in U87, U118, and GSCs at
0.5, 1, and 2 h after 0.05 nM EMAP II treatment compared
with the control group (P < 0.01), and the lowest points
were at 0.5 h. The expression of p-Akt/Akt, p-Akt/GAPDH,
p-mTOR/mTOR, and p-mTOR/GAPDH exhibited similar results
as above (Figures 4B,C). As shown in Figure 5A, compared
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FIGURE 3 | Effects of EMAP II on the expression and distribution of LC3 and p62/SQSTM1 in human GBM cells and GSCs. (A) Western blot analysis was
performed to detect the expression levels of LC3-II/LC3-I in U87, U118, and GSCs after treatment with 0.005 nM, 0.05 nM, 0.5 nM, and 5 nM EMAP II. Relative
integrated density value (IDV) of LC3-II/LC3-I are shown. (B) Western blot analysis was performed to detect the expression of LC3-II/LC3-I and p62/SQSTM1 in
U87, U118, and GSCs after treatment with 0.05 nM EMAP II for 0.5, 1, 2, 3, and 6 h, and EMAP II pretreatment with 3-MA. IDV of LC3-II/LC3-I and p62/SQSTM1
are shown. Values represented the means ± SD (n = 5, each). ∗∗P < 0.01 vs. control group, ##P < 0.01 vs. EMAP II group. (C) The up-regulation of LC3 and
down-regulation of p62/SQSTM1 in U87, U118, and GSCs were observed after treated with EMAP II alone or EMAP II plus 3-MA. Scale bar = 20 μm.
with the control group, cells treated with 0.05 nM EMAP II
at 0.5 h signiﬁcantly up-regulated the LC3-II expression and
down-regulated the p62/SQSTM1 expression in U87, U118,
and GSCs (P < 0.01). In addition, the LC3-II expression in
EMAP II+IGF-1 group was decreased, whereas the p62/SQSTM1
expression in this group was increased compared with EMAP
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FIGURE 4 | Effect of EMAP II on the expression of mTOR, PI3K, and Akt in human GBM cells and GSCs. Western blot analysis was performed to evaluate
the expression ratios of p-PI3K/PI3K, p-PI3K/GAPDH (A), p-Akt/Akt, p-Akt/GAPDH (B), p-mTOR/mTOR, and p-mTOR/GAPDH (C) in U87, U118, and GSCs
treated with EMAP II for 0.5, 1, 2, 3, and 6 h. Values represented the means ± SD (n = 5, each). ∗∗P < 0.01 vs. control group.
II group (P < 0.01). These results suggested that IGF-1 could
block the eﬀect of EMAP II on the expression of LC3-II and
p62/SQSTM1.Moreover, results from immunoﬂuorescence assay
were consistent with the above results (Figure 5B).
EMAP II Induced Mitophagy in Human
GBM Cells and GSCs
Due to the MMP was aﬀected by EMAP II, therefore we detected
whether mitophagy was induced by EMAP II. As shown in
Figures 6A,B, cells were stained with MitoTracker Deep Red FM
and anti-LC3 by immunoﬂuorescence, and results showed that
there was a signiﬁcant overlap between LC3 and MitoTracker
signals in EMAP II treated cells (P < 0.01), and co-treatment
with 3-MA blocked this eﬀect (P < 0.01). In addition, the
outer and inner mitochondrial membrane proteins (TOMM20
and TIMM23) was reduced by EMAP II, and co-treatment
with 3-MA rescued the inhibitory eﬀect induced by EMAP II
(Figures 6C–E).
Frontiers in Molecular Neuroscience | www.frontiersin.org 8 December 2015 | Volume 8 | Article 74
Ma et al. Autophagy in Human Glioblastoma Cells and GSCs
FIGURE 5 | Effects of EMAP II and IGF-1 on the expression of LC3 and p62/SQSTM1 in human GBM cells and GSCs. (A) Western blot analysis of the
expression levels of LC3-II/LC3-I and p62/SQSTM1 in U87, U118, and GSCs after treatment with EMAP II, IGF-1 and their combination. IDV of LC3-II/LC3-I and
p62/SQSTM1 are shown. Values represented the means ± SD (n = 5, each). ∗∗P < 0.01 vs. control group, ##P < 0.01 vs. EMAP II group. (B) The distribution and
expression of LC3 and p62/SQSTM1 in U87, U118, and GSCs. Scale bar = 20 μm.
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FIGURE 6 | EMAP II induced mitophagy in human GBM cells and GSCs. (A) The colocalization of LC3 and MitoTracker in U87, U118, and GSCs after cells
treated with EMAP II and the combination of EMAP II and 3-MA. (B) Quantitative analysis of the co-localization of LC3 with MitoTracker. Pictures are respective
magnification (n = 4, each). Scale bar = 20 μm. Western blot analysis of the expression of TOMM20 and TIMM23 in U87 (C), U118 (D) and GSCs (E) after cells
treated with EMAP II and the combination of EMAP II and 3-MA. Values represented the means ± SD (n = 5, each). ∗∗P < 0.01 vs. control group, ##P < 0.01 vs.
EMAP II group.
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FIGURE 7 | Effects of EMAP II and tauroursodeoxycholate (TUDC) on the expression of UPR-related proteins in human GBM cells and GSCs. Western
blot analysis of the expression of GRP78, p-eIF2α, eIF2α, and CHOP in U87 (A), U118 (B), and GSCs (C) after treatment with EMAP II, TUDC and their combination.
Values represented the means ± SD (n = 5, each). ∗P < 0.05 and ∗∗P < 0.01 vs. control group, ##P < 0.01 vs. EMAP II group.
EMAP-II Induced the Activation of
Endoplasmic Reticulum (ER) Stress in
Human GBM Cells and GSCs
Several studies reported that autophagy could be induced by
unfolded protein response (UPR) which is the major endoplasmic
reticulum (ER) stress pathway (Tsai and Weissman, 2010).
To examine whether ER stress was induced by the EMAP-II
treatment, levels of the UPR-related proteins GRP78, p-eIF2α,
eIF2α, and CHOPwere measured after cells treated with 0.05 nM
EMAP II for 0.5 h, (TUDC, an ER stress inhibitor) or their
combination. As shown in Figure 7A, the expression of GRP78,
p-eIF2α, and CHOP were increased in EMAP II group compared
with the control group in U87 cells (P < 0.01). In addition, the
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expression of GRP78, p-eIF2α, and CHOP were decreased in
the combination of EMAP II with TUDC group compared with
the EMAP II group (P < 0.01). The similar results were also
observed in U118 cells and GSCs (Figures 7B,C). These results
suggested that human GBM cells and GSCs exposed to EMAP-II
experienced ER stress.
The Combination of EMAP II with
Rapamycin Inhibited Cell Proliferation,
Migration, and Invasion of Human GBM
Cells and GSCs
The abilities of cell proliferation, migration and invasion were
investigated to further evaluate the eﬀects of the combination
of EMAP II with rapamycin on the biological behaviors
of human GBM cells and GSCs. As shown in Figure 8A,
compared with the control group, the cell proliferation of U87,
U118, and GSCs were inhibited after EMAP II or rapamycin
treatment (P < 0.01). The cell proliferation of U87, U118,
and GSCs was more remarkably inhibited by the combination
of EMAP II with rapamycin compared with the use of either
agent alone (P < 0.05). As shown in Figure 8B, scratch
wound healing assay showed that the migration of U87 and
U118 cells in EMAP II or rapamycin groups were inhibited
compared with that in the control group (P < 0.01). In
addition, EMAP II in combination with rapamycin displayed
even greater inhibitory eﬀect on the migration of U87 and
U118 cells than either EMAP II or rapamycin alone (P < 0.05).
Subsequently, we employed the transwell migration assay to
further deﬁne the migration of U87, U118 and GSCs, and
the results were similar as above (Figure 8C). As shown in
Figure 8D, the invasion of U87, U118, and GSCs in EMAP
II or rapamycin groups were inhibited compared with that
in the control group (P < 0.01). EMAP II in combination
with rapamycin displayed even greater inhibitory eﬀect on
the invasion of U87, U118, and GSCs than either EMAP II
or rapamycin alone (P < 0.05). The above results suggested
that the combination of EMAP II with rapamycin inhibited
the malignant biological behaviors of human GBM cells and
GSCs.
The Combination of EMAP II with
Rapamycin Produced the Smallest
Tumors In Vivo
The growth-inhibitory eﬀects of EMAP-II and rapamycin were
further tested in xenografted mice. Representative images of
mice and tumors were shown in Figures 9A,B. Tumor growth
was signiﬁcantly suppressed in nude mice treated with EMAP-
II, rapamycin or the combination of EMAP II with rapamycin
compared with that in the control group (P < 0.01). Combined
treatment of EMAP II with rapamycin produced further
inhibition on tumor growth than EMAP-II or rapamycin group
(P < 0.05) (Figures 9C,D). These results showed that nude mice
carrying humanGBM cells and GSCs which were treated with the
combination of EMAP II with rapamycin produced the smallest
tumors.
DISCUSSION
In the present study, we found that low-dose EMAP II inhibited
the cell viability and MMP in human GBM cells and GSCs
by inducing autophagy, accompanied by the up-regulation of
LC3-II and the down-regulation of p62/SQSTM1. Moreover, we
provided the evidence that cells treated with EMAP-II inhibited
the PI3K/Akt/mTOR signal pathway, and experienced mitophagy
and ER stress. Finally, the combination of EMAP II and
rapamycin showed the inhibitory eﬀect on the cell proliferation,
migration, and invasion of GBM cells and GSCs in vitro and
in vivo.
Endothelial-monocyte activating polypeptide II has
been recognized as an angiostatic mediator that suppresses
neovascularization, induced endothelial cell apoptosis, inhibited
tumor vessel formation, and suppressed primary and metastatic
tumor growth (Schwarz et al., 1999; Berger et al., 2000). In
addition, EMAP II was found to reduce the proliferation of
tumor cells within the neoplastic tissue (Schwarz and Schwarz,
2004). Our results showed that low-dose EMAP II signiﬁcantly
inhibited the cell viability of human GBM cells and GSCs at
0.5 h. To further analyze the possible mechanisms, cells were
pretreated with autophagy inhibitor 3-MA or broad-spectrum
caspase inhibitor Z-VAD. Our results showed that only 3-MA
blocked the inhibitory eﬀect of EMAP II on the cell viability.
It has been reported that EMAP II inhibited the growth of
endothelial cells and pancreatic cancer cells, and the inhibitory
eﬀect was associated with the inhibition of tumor vascular
endothelium growth (Schwarz and Schwarz, 2004). However,
the underlying mechanism in regarding to this inhibition may
involve many aspects, such as EMAP II inhibited the growth
of pancreatic cancer through inhibiting ﬁbronectin-dependent
proliferation (Schwarz et al., 2010a,b) or inhibited tumor
angiogenesis by inducing endothelial cell apoptosis (Berger et al.,
2000). However, the dose of EMAP II described in our present
study has not been reported to induce apoptosis in GBM cells
and GSCs. Mitochondrial functional status is closely related to
cancerogenesis, and MMP is one of the important parameters of
mitochondrial functional status. Our results showed that EMAP
II decreased the MMP and formed a trough at 0.5 h. Meanwhile,
EMAP II-induced MMP inhibition was blocked by 3-MA,
indicating that EMAP II inhibited cell viability and impaired
the mitochondrial function might be associated with autophagy.
Additionally, we observed the existence of autophgosomes and
the increased punctate distribution of LC3 under the treatment
of 0.05 nM EMAP II for 0.5 h, and 3-MA blocked this eﬀect.
Thus, our results demonstrated that the cytotoxicity of EMAP
II in human GBM cells and GSCs was induced by autophagy.
Moreover, mitochondria have been described as a source of
autophagosome biogenesis, and plays a key role in the cross-talk
between autophagy and apoptosis regulation (Hailey et al.,
2010; Strappazzon et al., 2011). Mitophagy is a process through
which dysfunctional mitochondria are selectively removed by
autophagy (Kim et al., 2007). Our results showed that EMAP II
induced mitophagy in human GBM cells and GSCs, suggesting
that the mitophagy might be involved in the cytotoxicity induced
by EMAP II.
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FIGURE 8 | Effects of EMAP II and rapamycin on the cell proliferation, migration, and invasion of human GBM cells and GSCs. (A) Cell proliferation of
U87, U118, and GSCs was assessed by CCK8 assay. (B) The migration of U87 and U118 cells was measured by wound healing assay. (C) Cell migration of U87,
U118, and GSCs was measured by transwell assay. (D) Cell invasion of U87, U118, and GSCs was measured by transwell assay. Values represented the
means ± SD (n = 5, each). ∗∗P < 0.01 vs. control group; #P < 0.05 vs. EMAP II group; P < 0.05 vs. rapamycin group.
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FIGURE 9 | The in vivo study of EMAP II and rapamycin. Representative images of mice (A) and tumors (B) obtained from the xenografted mice with or without
treatment for 18 weeks. (C) Tumor growth curve in nude mice. (D) Tumor weight in nude mice. ∗∗P < 0.01 vs. control group, #P < 0.05 vs. EMAP-II group,
P < 0.05 vs. rapamycin group.
LC3, an autophagy marker, exists in cells in two forms: LC3-
I and LC3-II. As a marker of autophgosomes, the expression
level of LC3-II reﬂects the number of autophgosomes to a certain
extent (Levine and Yuan, 2005). Our study revealed that EMAP
II signiﬁcantly increased LC3-II expression at the concentrations
of 0.05, 0.5, and 5 nM. The expression of LC3-II was increased
to peak level at 0.5 h under the treatment of 0.05 nM EMAP II
with the punctuate of LC3 aggregated in GBM cells and GSCs.
P62/SQSTM1 is a multifunctional ubiquitinated protein coupled
to LC3, which is involved in the formation of autophgosomes as
a regulatory factor and is degraded in the middle or late phase
of autophagy. Therefore, the total expression level of intracellular
p62/SQSTM1 was negatively correlated with autophagic activity
(Bjorkoy et al., 2005). Consistent with the above study, the eﬀect
of EMAP II on the p62/SQSTM1 expression was opposite to
LC3-II. P62/SQSTM1 plays important roles in the regulation
of intracellular autophagy, proteasome and NF-κB signaling
pathway. It has been reported that the repression of autophagy
led to over-expression of p62/SQSTM1, which promoted tumor
cell proliferation by various mechanisms such as regulating
NF-κB signaling pathway, the accumulation of oxygen radicals,
DNA damage and other processes (Kongara and Karantza, 2012;
Moscat and Diaz-Meco, 2012).
PI3K/Akt/mTOR signal pathway is mainly involved in
regulating cell growth, apoptosis and other important cellular
signal transduction (Cherla et al., 2009; Zhang et al., 2009).
Furthermore, PI3K/Akt/mTOR is a critical regulatory pathway
in autophagy response (Takeuchi et al., 2005; Guertin and
Sabatini, 2007). Recent study revealed that PI3K/Akt/mTOR
signal pathway would be commonly activated in human glioma
cells (Qiao et al., 2013; Shin et al., 2013; Xu et al., 2013). To further
investigate the possible mechanism involved in this process,
we studied the eﬀect of EMAP II on P13K, Akt, and mTOR
signal molecules. Our study found that the PI3K/Akt/mTOR
signal pathway was inhibited at 0.5, 1, and 2 h after 0.05 nM
EMAP II treatment, and the PI3K/Akt agonist IGF-1 signiﬁcantly
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blocked the eﬀect of EMAP II on the expression of LC3-II
and p62/SQSTM1, suggesting the EMAP-II-induced autophagy
is dependent of PI3K/Akt/mTOR signal pathway. The eﬀect
of some anti-neoplastic drugs are also associated with the
regulation of PI3K/Akt/mTOR signal pathway. Chlorpromazine
was reported to induce autophagic cell death in U87 cells
through inhibiting Akt/mTOR (Shin et al., 2013). The inhibition
of mTOR cascade reaction pathway was also involved in the
synergistic anti-glioma eﬀect of niclosamide in combination with
emozolomide (Takeuchi et al., 2005).
The endoplasmic reticulum (ER) is responsible for protein
folding, lipid and sterol biosynthesis, and intracellular calcium
storage (Schroder, 2008). Accumulation of unfolded proteins
in the ER, nutrient deprivation, calcium imbalance, oxidative
stress, metabolic alterations, and environmental acidity activate
UPR signaling to enable adaptation to perturbations and to
relieve ER stress by activating three ER-resident transmembrane
transducers (Kim et al., 2008; Cao and Kaufman, 2012).
Autophagy could supplement cellular metabolism by digesting
damaged organelles or misfolded proteins. In addition, recent
studies have conﬁrmed that ER stress is a potent inducer of
autophagy (Cook et al., 2014; Shen et al., 2014), thus the
levels of the UPR-related proteins GRP78, p-eIF2α, eIF2α, and
CHOP were measured. Our results showed that the expression of
GRP78, p-eIF2α, and CHOP were increased in EMAP II group,
TUDC attenuated the expression of these induced by EMAP
II, suggesting that cells exposed to EMAP-II experienced ER
stress. In addition, we have demonstrated that EMAP II induced
cell autophagy in human GBM cells and GSCs, suggesting
that autophagy induced by EMAP-II might be related with ER
stress.
Rapamycin, an mTOR inhibitor, is widely used in the
experimental and clinical researches for anti-neoplastic drugs
(Nakamura et al., 2014; Wang et al., 2014). The mTOR inhibitors
have been used in the clinical trial for several tumors, among
them are rapamycin analogs temsirolimus and everolimus
which have been used to treat some tumors (Leung et al.,
2011; Fasolo and Sessa, 2012; Voss et al., 2014). In the study
of glioma treatment, everolimus led to cell cycle arrest and
increased radiosensitivity in malignant glioma cells by activating
autophagy response (Scaringi et al., 2013). Therefore, we further
evaluated the eﬀects of EMAP II alone or in combination with
rapamycin on the biological behaviors of human GBM cells and
GSCs. Our results showed that both EMAP II and rapamycin
signiﬁcantly inhibited the cell proliferation, migration, and
invasion of human GBM cells and GSCs. The combination
of these two agents displayed more inhibitory eﬀect on the
malignant behavior of these cells. The in vivo studies also showed
that the combination of EMAP II with rapamycin produced
the smallest tumors. In line with our study, previous study
have shown that rapamycin could inhibit the proliferation of
glioma cells by inducing autophagy (Bray et al., 2012), which
contributed to the anti-glioma eﬀect of EMAP II combined with
rapamycin.
Asmentioned above, our study illustrated that the cytotoxicity
of low-dose EMAP II in human GBM cells and GSCs was
induced by autophagy, accompanied by the inhibition of
PI3K/Akt/mTOR signal pathway, mitophagy and ER stress.
Furthermore, EMAP II combined with rapamycin signiﬁcantly
inhibited cell proliferation, migration and invasion of human
GBM cells and GSCs. Thus, the combined therapy of EMAP II
with agents that can inhibit P13K/Akt/mTOR signal pathway may
be a new novel therapeutic strategy for the treatment of human
glioblastoma.
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